Skip to main content
Clinical Trials/NL-OMON39520
NL-OMON39520
Completed
Phase 2

Evaluation of the effect of psycho-oncological intervention on well-being of patients with advanced prostate cancer on LHRH analogs and their partners. A randomized controlled pilot study. - EXPEDIENT

Ipsen Pharmaceuticals0 sites50 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
coping / adaptation
Sponsor
Ipsen Pharmaceuticals
Enrollment
50
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Ipsen Pharmaceuticals

Eligibility Criteria

Inclusion Criteria

  • \- Patient and partner must give written (personally signed and dated) informed consent before completing any study\-related procedure.
  • \- Histologically confirmed diagnosis of prostate cancer on biopsy.
  • \- Locally advanced or metastasised prostate cancer in need of hormonal treatment.
  • \- On LHRH analogue treatment for a minimum of 5 months (at inclusion).
  • \- Patients and their partner are able to fill out questionnaires, attend group sessions and give consent
  • \- Having a female partner

Exclusion Criteria

  • \-Serious psychiatric difficulties
  • \-Life expectancy \< 12 months

Outcomes

Primary Outcomes

Not specified

Similar Trials